Needham Reiterates Buy on Cidara Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a price target of $3.
September 22, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Cidara Therapeutics and maintained a price target of $3.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Cidara Therapeutics. The maintained price target of $3 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100